The pharmaceutical sector has changed! Guizhou Bailing rose to the limit, Xinhua Pharmaceutical, Yiling Pharmaceutical and so on went higher

【Pharmaceutical Network Pharmaceutical Stock Market】News on December 6, the pharmaceutical sector has changed, from the perspective of individual stocks, Guizhou Bailing has a limit, in addition, Xinhua Pharmaceutical, Yiling Pharmaceutical and many other stocks have gone higher
.
Among them, Xinhua Pharmaceutical opened up 5%, as of 9:34, up 7.
28%, at 25.
21 yuan, with a transaction of 664 million and a turnover rate of 6.
13%.

On the news, Xinhua Pharmaceutical said on the interactive platform on December 5 that the company is an important manufacturer of antipyretic and analgesic APIs in the world, including ibuprofen, aspirin, metamizole sodium, aminopyrine, antipyrine, isoproantipyrine, tramadol, meloxicam and other varieties
.
The company's main varieties, production capacity and scale are in an advantageous position, and has realized the supporting industrial chain, passed the European and American standardized market quality certification, and the market competitiveness is very obvious
.
The actual market share of the company ibuprofen is close to 40%.

As of 9:34, Yiling Pharmaceutical rose nearly 3% to 46.
93 yuan, with a transaction of 1.
245 billion yuan and a turnover rate of 1.
96%.

The analysis believes that the rise of the stock is mainly closely related to the company's product Lianhua Qingwen
.
It is reported that Lianhua Qingwen series has become an important source of income for Yiling Pharmaceutical, contributing nearly half of the revenue
.
In 2021, the total operating income of Yiling Pharmaceutical reached 10.
117 billion yuan, a year-on-year increase of 15.
19%; The net profit was 1.
344 billion yuan, a year-on-year increase of 10.
27%.

Among them, the revenue of respiratory system products where Lianhua Qingwen series is located rose to 40.
6%, and the revenue of cardiovascular and cerebrovascular products accounted for 44.
82%.

As of 9:34, Guizhou Bailing rose more than 10% to 10.
00 yuan, with a transaction of 837 million and a turnover rate of 7.
89%.

It is worth mentioning that Guizhou Bailing also achieved a one-word limit yesterday, and the stock price has now hit a new high
since April this year.
On the news, it is mainly related to the official publication of a paper in the national comprehensive medical journal "Physician Online" on the evening of December 2, which mentioned the role of
Guizhou Bailing's "cough stop syrup".
The industry believes that cough stop syrup has the advantages of low price and good taking experience, and based on the above research results, it is expected to become a regular drug
for people to have at home.
With the implementation of the "20 Articles", the demand for traditional Chinese medicine for cold and cough may increase
significantly.
Recently, traditional Chinese medicine stocks have risen again, and the industry believes that in addition to the growth of related drugs brought about by the "20 articles" and autumn and winter, it is mainly closely related to a series of favorable policy support behind it
.
The development of traditional Chinese medicine has been elevated to a national strategy, and in recent years, it has ushered in more favorable policy support, covering almost the entire industrial chain of traditional Chinese medicine, involving upstream Chinese herbal medicine planting, traditional Chinese medicine service system, talent construction, inheritance and innovation, open development, medical insurance payment, review and approval
, etc.
Among them, in terms of talent construction, in June this year, the four departments jointly issued the "Opinions on Strengthening the Work of Chinese Medicine Talents in the New Era", which clarifies that "by 2025, all community service centers and township hospitals will set up Chinese medicine halls and allocate Chinese medicine doctors"
.
Not long ago, the State Administration of Traditional Chinese Medicine issued the "14th Five-Year Plan for the Development of Chinese Medicine Talents"
.
The plan proposes that by 2025, the total number of traditional Chinese medicine personnel in medical and health institutions will exceed 1 million; The number of practicing (assistant) physicians in the TCM category per 1,000 population exceeds 0.
62; the number of general practitioners in TCM category per 10,000 population exceeds 0.
79; and the proportion of practicing (assistant) physicians in TCM category in public TCM hospitals above level II is greater than 60%.

Many securities institutions believe that the traditional Chinese medicine industry is ushering in a period of policy
dividends.
With the frequent emergence of favorable policies, the traditional Chinese medicine industry will usher in a new round of development opportunities
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.